Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: A randomized trial

JAMA

Volumn 309, Issue 23, 2013, Pages 2449-2456

  Heijstek, Marloes W ^a   Kamphuis, Sylvia ^b   Armbrust, Wineke ^c   Swart, Joost ^a,d   Gorter, Simone ^e   De Vries, Lara D ^a   Smits, Gaby P ^f   Van Gageldonk, Pieter G ^f   Berbers, Guy A M ^f   Wulffraat, Nico M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; METHOTREXATE;

ANTIBODY SPECIFICITY; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE REACTION; JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVACCINATION; SCHOOL CHILD; VACCINATION;

EID: 84879093351     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.6768     Document Type: Article

References (25)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778.
2. Beukelman T, Xie F, Chen L, et al SABER Collaboration. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(8):2773-2780.
3. Salvana EM, Salata RA. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev. 2009;22(2):274-290.
4. British Society for Rheumatology. Vaccinations in the Immunocompromised Person: Guidelines for the Patient Taking Immunosuppressants, Steroids and the New Biologic Therapies. London, England: British Society for Rheumatology; 2002.
5. Chantler JK, Tingle AJ, Petty RE. Persistent rubella virus infection associated with chronic arthritis in children. N Engl J Med. 1985;313(18):1117-1123. (Pubitemid 16223212)
6. Ray P, Black S, Shinefield H, et al Vaccine Safety Datalink Team. Risk of chronic arthropathy among women after rubella vaccination. JAMA. 1997;278(7):551-556. (Pubitemid 27353603)
7. Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford). 2009;48(2):144-148.
8. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(10):1384-1387. (Pubitemid 47492487)
9. Petty RE, Southwood TR, Manners P, et al International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392. (Pubitemid 38160763)
10. Heijstek MW, Ott de Bruin LM, Bijl M, et al EULAR. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704-1712.
11. Consolaro A, Ruperto N, Bazso A, et al Paediatric Rheumatology International Trials Organisation. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658-666.
12. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202-1209. (Pubitemid 27430130)
13. Lovell DJ, Ruperto N, Goodman S, et al Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810-820.
14. Centers for Disease Control and Prevention. Manual for the Surveillance of Vaccine-Preventable Diseases. In: Roush SW, McIntyre L, Baldy LM, eds. 4th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2008.
15. Rümke HC, Visser HK. Vaccinaties op de kinderleeftijd anno 2004, I: effectiviteit en acceptatie van het Rijksvaccinatieprogramma. Ned Tijdschr Geneeskd. 2004;148(8):356-363. (Pubitemid 38249842)
16. Smits GP, van Gageldonk PG, Schouls LM, van der Klis FR, Berbers GA. Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus. Clin Vaccine Immunol. 2012;19(3):396-400.
17. Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine. 2012;30(33):4907-4920.
18. Andrews N, Pebody RG, Berbers G, et al. The European Sero-Epidemiology Network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiol Infect. 2000;125(1):127-141.
19. Consolaro A, Bracciolini G, Ruperto N, et al Paediatric Rheumatology International Trials Organization. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the Juvenile Arthritis Disease Activity Score. Arthritis Rheum. 2012;64(7):2366-2374.
20. Korematsu S, Miyahara H, Kawano T, et al. A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period. Vaccine. 2009;27(37):5041-5042.
21. Scheinberg M, Guedes-Barbosa LS, Mangueira C, et al. Yellow fever revaccination during infliximab therapy. Arthritis Care Res (Hoboken). 2010;62(6):896-898.
22. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055-1065.
23. Pebody RG, Gay NJ, Hesketh LM, et al. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine. 2002;20(7-8):1134-1140. (Pubitemid 34135949)
24. Pileggi GS, de Souza CB, Ferriani VP. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res (Hoboken). 2010;62(7):1034-1039.
25. Frenkel LM, Nielsen K, Garakian A, Jin R, Wolinsky JS, Cherry JD. A search for persistent rubella virus infection in persons with chronic symptoms after rubella and rubella immunization and in patients with juvenile rheumatoid arthritis. Clin Infect Dis. 1996;22(2):287-294. (Pubitemid 26056157)